The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC).
 
Anthony Serritella
Stock and Other Ownership Interests - Anthony Serritella
 
Daniel H. Shevrin
Speakers' Bureau - Bayer; Sanofi/Aventis
 
Elisabeth I. Heath
Honoraria - Bayer; Dendreon; Sanofi; Seagen
Consulting or Advisory Role - Agensys
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Esanik (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inovio Pharmaceuticals (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Oncolys BioPharma (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Other Relationship - Caris Centers of Excellence
 
James Lloyd Wade
Employment - Johnson & Johnson (I)
Stock and Other Ownership Interests - Abbott (I); Celgene; GlaxoSmithKline (I); Johnson & Johnson (I); Novartis (I)
 
Elia Martinez
No Relationships to Disclose
 
Theodore Karrison
No Relationships to Disclose
 
Walter Michael Stadler
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; CVS Caremark; Eisai; Merck; Pfizer; Roche/Genentech; Sotio
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst)
Other Relationship - American Cancer Society; UpToDate
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
Research Funding - Abbvie; Astellas Pharma; Incyte; Janssen Oncology; Macrogenics
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics